Pharmaceuticals & Therapeutics

Adlai Nortye licenses its promising pan-RAS cancer inhibitor to ASK Pharm for Greater China in a deal valued at up to $230 million.

For the 13th consecutive year, Karmanos Cancer Institute is named a top US hospital, a distinction driven by patient safety and women's care preferences.

Diamyd Medical's pivotal Phase 3 trial gets a nine-month acceleration, raising hopes for a new precision therapy that preserves insulin production.

As pharma moves beyond small molecules, a new integrated platform helps developers navigate the challenges of PROTACs, peptides, and antibody drugs.

An FDA setback for its new mastitis drug prompts ImmuCell to double down on its profitable calf health franchise, First Defense®, in a major strategic shift.

A unique partnership brings accessible genetic testing to Boca Raton, using a community race to empower families with critical health knowledge.

In a landmark deal, BioMarin acquires Amicus Therapeutics, gaining high-growth drugs and reshaping the landscape for patients with rare genetic disorders.

In a fierce biotech talent war, Senti Bio's new equity grant for a key hire signals a strategic push for its gene therapy pipeline amid market volatility.

Facing a critical cash shortfall, Cue Biopharma turns to the market, betting its promising cancer and autoimmune pipeline can win over investors.

Facing financial headwinds, Celularity lands a critical $12M from a top investor to push its ambitious anti-aging and regenerative therapies forward.

As pharma sells GLP-1s directly to patients, doctors are split on the new model. Is it a lifeline for access or a risk to integrated patient care?

A simple, low-cost heart pill may hold the key to treating Alzheimer's and kidney disease. CardioPharma is now funding research to unlock its potential.

Picard Medical rings the NYSE bell, but its stock's volatile journey reflects the high-stakes gamble on its next-generation artificial heart technology.

The biotech upstart will present a bold pipeline, including a head-to-head trial against a market leader and a first-in-class autoimmune eye disease therapy.

Dr. Philip Golinsky’s alumni award from Life University marks a milestone for RxWellness and the growing trend of integrated, non-surgical patient care.

With trial data showing an average 23% body weight loss, Novo Nordisk's new combination drug CagriSema could usher in a powerful new era for medicine.

The neuro-focused biotech just acquired a late-stage cancer drug, securing massive funding. Is this a brilliant diversification or a high-stakes gamble?

Bolstered by positive clinical data and top investors, Kalaris Therapeutics extends its runway to advance TH103, a next-gen treatment for neovascular AMD.

Early Phase 1a data for Kalaris's new nAMD drug shows significant vision improvement and potential for extended durability, aiming to reduce patient burden.

A key trial update de-risks Tenax Therapeutics' pivotal study for a novel heart failure therapy, boosting confidence in its path to market.